Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models
dc.contributor.author | Rosenke, K | |
dc.contributor.author | Jarvis, Michael A | |
dc.contributor.author | Feldmann, F | |
dc.contributor.author | Schwarz, B | |
dc.contributor.author | Okumura, A | |
dc.contributor.author | Lovaglio, J | |
dc.contributor.author | Saturday, G | |
dc.contributor.author | Hanley, PW | |
dc.contributor.author | Meade-White, K | |
dc.contributor.author | Williamson, BN | |
dc.contributor.author | Hansen, FA | |
dc.contributor.author | Pérez-Pérez, L | |
dc.contributor.author | Leventhal, S | |
dc.contributor.author | Tang-Huau, T-L | |
dc.contributor.author | Callison, J | |
dc.contributor.author | Haddock, E | |
dc.contributor.author | Stromberg, KA | |
dc.contributor.author | Sewell, G | |
dc.contributor.author | Scott, D | |
dc.contributor.author | Bosio, CM | |
dc.contributor.author | Hawman, DW | |
dc.contributor.author | de Wit, E | |
dc.contributor.author | Feldmann, H | |
dc.date.accessioned | 2021-08-09T12:41:39Z | |
dc.date.issued | 2020-12-03 | |
dc.identifier.issn | 2379-3708 | |
dc.identifier.issn | 2379-3708 | |
dc.identifier.other | 143174 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/17498 | |
dc.description.abstract |
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in 2 animal disease models. The standard human malaria HCQ prophylaxis (6.5 mg/kg given weekly) and treatment (6.5 mg/kg given daily) did not significantly benefit clinical outcome, nor did it reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. Similarly, when used for prophylaxis or treatment, neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Results from these 2 preclinical animal models may prove helpful in guiding clinical use of HCQ for prophylaxis/treatment of COVID-19. | |
dc.format.extent | 143174- | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | American Society for Clinical Investigation | |
dc.subject | COVID-19 | |
dc.subject | Cytokines | |
dc.subject | Drug screens | |
dc.subject | Molecular biology | |
dc.subject | Therapeutics | |
dc.subject | Animals | |
dc.subject | Antiviral Agents | |
dc.subject | COVID-19 | |
dc.subject | Chlorocebus aethiops | |
dc.subject | Cricetinae | |
dc.subject | Cytokines | |
dc.subject | Disease Models, Animal | |
dc.subject | Drug Evaluation, Preclinical | |
dc.subject | Humans | |
dc.subject | Hydroxychloroquine | |
dc.subject | Lung | |
dc.subject | Macaca mulatta | |
dc.subject | Male | |
dc.subject | SARS-CoV-2 | |
dc.subject | Treatment Outcome | |
dc.subject | Vero Cells | |
dc.subject | Viral Load | |
dc.subject | Virus Replication | |
dc.subject | Virus Shedding | |
dc.subject | COVID-19 Drug Treatment | |
dc.title | Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, N.I.H., Intramural | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000599321000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 23 | |
plymouth.volume | 5 | |
plymouth.publication-status | Published | |
plymouth.journal | JCI Insight | |
dc.identifier.doi | 10.1172/jci.insight.143174 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Health and Community | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2020-10-16 | |
dc.rights.embargodate | 2021-8-11 | |
dc.identifier.eissn | 2379-3708 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1172/jci.insight.143174 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-12-03 | |
rioxxterms.type | Journal Article/Review |